- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
11
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
11 companies
Merck
Market Cap: US$276.4b
Operates as a healthcare company worldwide.
MRK
US$110.23
7D
-5.9%
1Y
32.5%
Illumina
Market Cap: US$19.4b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$128.52
7D
-3.3%
1Y
66.4%
Exelixis
Market Cap: US$11.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$44.65
7D
2.4%
1Y
16.2%
ACADIA Pharmaceuticals
Market Cap: US$3.7b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$22.30
7D
1.0%
1Y
52.1%
ADMA Biologics
Market Cap: US$2.5b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$10.93
7D
1.4%
1Y
-54.7%
Aurinia Pharmaceuticals
Market Cap: US$2.1b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$16.37
7D
2.6%
1Y
104.6%
Theravance Biopharma
Market Cap: US$847.6m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.81
7D
0.5%
1Y
72.4%
CorMedix
Market Cap: US$613.7m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.82
7D
6.0%
1Y
-14.3%
Abeona Therapeutics
Market Cap: US$306.6m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.34
7D
-2.6%
1Y
-0.2%
Compugen
Market Cap: US$293.1m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.92
7D
1.4%
1Y
102.8%
Oramed Pharmaceuticals
Market Cap: US$155.7m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$4.11
7D
7.3%
1Y
83.5%